Clinical trialNCT01221246CompletedPhase 2Interventional

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

SponsorGenervon Biopharmaceuticals, LLCEnrollment34Stroke

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to determine whether the investigational drug GM602, is effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot blocking the flow of blood through one, or more of the blood vessels supplying the brain) when administered up to 18 hours after symptoms begin.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anand Vaishnav, M.D.
University of Louisville
Principal Investigator
clinicaltrials.gov ↗
Arbi G Ohanian, MD
Huntington Memorial Hospital
Principal Investigator
clinicaltrials.gov ↗
David Brown, MD
Hoag Memorial Hospital Presbyterian
Principal Investigator
clinicaltrials.gov ↗
Jeff Saver, MD
UCLA Stroke Center
Principal Investigator
clinicaltrials.gov ↗
Mauricio Concha, M.D.
Sarasota Memorial Hospital
Principal Investigator
clinicaltrials.gov ↗
Nobl Barazangi, M.D.
California Pacific Medical Center Research Institute
Principal Investigator
clinicaltrials.gov ↗
Sidney Starkman, MD
UCLA Stroke Center
Principal Investigator
clinicaltrials.gov ↗
Stephan A Mayer, M.D.
Columbia University
Principal Investigator
clinicaltrials.gov ↗
Thomas G Devlin, M.D.
University Erlanger Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucla Stroke Center (departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center)
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Huntington Memorial Hospital Stroke Center
Pasadena, California, United States
California Pacific Medical Center Research Institute
San Francisco, California, United States
Sarasota Memorial Hospital
Sarasota, Florida, United States
University of Louisville
Louisville, Kentucky, United States
Columbia University Medical Center
New York, New York, United States
University Erlanger Hospital
Chattanooga, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GM602Placebo Comparator

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Mar 2011
Primary completion: 7 Jul 2016
Completion: 7 Jul 2016
Last update posted: 12 Aug 2019
Registered enrollment: 34
Registry id: NCT01221246

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.